Clindamycin Vaginal
78 interactions 680 cited referencesVaginal clindamycin is used to treat bacterial vaginosis (an infection caused by an overgrowth of harmful bacteria in the vagina). Clindamycin is in a class of medications called lincomycin antibiotics. It works by slowing or stopping the growth of bacteria. Vaginal clindamycin cannot be used to treat vaginal irritatio… Read the full Clindamycin Vaginal drug information page →
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Major
Clindamycin Vaginal Ranolazine Aspruzyo Increased exposure of CYP3A4 substrate Details Clindamycin Vaginal Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Clindamycin Vaginal Repotrectinib Augtyro Reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Clindamycin Vaginal Ribociclib Kisqali Increased exposure of CYP3A4 substrate and an increased risk of CYP3A4 substrate-related adverse reactions Details Clindamycin Vaginal Selpercatinib Retevmo Increased substrate exposure and an increased risk for adverse effects Details Clindamycin Vaginal Sevabertinib Hyrnuo Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Clindamycin Vaginal Sotorasib Lumakras Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Clindamycin Vaginal Suzetrigine Journavx Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Clindamycin Vaginal Taurursodiol Decreased exposure of the CYP3A4 substrate Details Clindamycin Vaginal Tazemetostat Tazverik Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Clindamycin Vaginal Tocilizumab Actemra Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Clindamycin Vaginal Tovorafenib Ojemda Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Clindamycin Vaginal Treosulfan Grafapex Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse and serious life-threatening toxicit... Details Clindamycin Vaginal Tucatinib Tukysa Increased exposure to CYP3A substrate and risk of toxicity Details Clindamycin Vaginal Vonoprazan Voquezna Increased CYP3A substrates exposure Details Clindamycin Vaginal Vorasidenib Voranigo Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Clindamycin Vaginal Voriconazole Vfend Increased CYP3A4 substrates exposure and an increased efficacy of CYP3A4 substrates-related adverse effects DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist